we loved az and medimmune because of their aggressiveness and positioning in this competitive area. > a long time. why now? why give away some of the upside now or you just finally have so many things going it's worth it to partner for this element? >> we're partnering on first ino 3112 for head and neck and cervical cancer but we have plenty of other products in the pipeline, prostate cancer, breast, lung, and pancreas. so we can build on the strong partnership with medimmune, who by the way, has a very strong pipeline of check point inhib or immune therapy models that can be used in combination of our products. this is a perfect one-two punch to go after these tough to treat cancer cells. >> it's a big day for your company. that's the president and ceo of inovio pharmaceuticals. there is a lot of articles about it today. attention investors! vectorvest mobile is here and it's free! make faster, smarter, better trading decisions with ctorvest mobile. the most powerful app or managing your portfolio from the palm of your hand. only vectorvest mobile analyzes, ranks and graphs... ...ov